Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemether + lumefantrine for uncomplicated Plasmodium falciparum malaria in children in the Central African Republic
ACTRN12616001451493Phase 4Completed
- Sponsor
- Ministry of Health
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of artemether and lumefantrine in malaria and Falciparum malaria (PF), sponsored by Ministry of Health. Primary endpoints: Treatment failure rate, Adequate clinical and parasitological response and 1 more. Started Jan 2017; status: completed.
02
Drugs
artemetherlumefantrine
03
Conditions
malariaFalciparum malaria (PF)
Beyond the preview
Go deeper on ACTRN12616001451493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001451493.